Abstract
Gastrointestinal (GI) disorders are set to affect over 250 million people in
the seven largest pharma markets, by 2012. As generations of people become
more obese and consume increasingly poor diets then so too will the number of
people suffering from these disorders rise.
At present, the pharmaceutical prescription market to treat GI disorders
market is valued at just over $20 billion, reflecting that it is one of the
largest and most important therapeutic areas in the pharmaceutical industry.
Visiongain has just produced a business intelligence report, Gastrointestinal
Disorders 2007-2012, which addresses the state of this market, and assesses
how it will develop in the future. Are you involved in this market area? Will
the future of this market affect your business?
AstraZeneca' s Nexium is currently the most successful GI drug available in the
market, based on sales revenues totaling more than $6 billion. What is the
future for Nexium? How will its impact shape the GI market? Will other GI
drugs reach blockbuster status? If so, which ones? Find out in this vital
report.
Another example of change in the GI market is the withdrawal of Novartis' s
from the US market, due to safety and efficacy issues. What effects will this
have on the other GI drugs? How will this affect the overall GI market? What
does the future hold for Novartis and Zelnorm? These are all crucial questions
that need answers, which can be found by buying this visiongain report.
Visiongain' s World Gastrointestinal Disorders report includes three major
classes of product which visiongain believes will extensively occupy the GI
market. These are:
- Proton Pump Inhibitors (PPIs)
- Histamine H2 Receptor Antagonists
- Other Leading GI agents
Which new drugs will be marketed? Which drugs will have the most impact on the
market? Most importantly, what are the future prospects of the GI market?
The following crucial aspects of the GI market are discussed:
- The current world GI market
- SWOT Analysis of the GI market
- Revenue Forecasts for all the drugs analysed 2007-2012
- Market Activity
- Geographical breakdown of GI market
- Potential treatment population forecasted to 2012 for major leading global
markets
- Discussion on comparative pricing of the major GI drugs
- Analysing the major generic/substitute products
- Detailed information on pipeline products
- Discussion on possible future strategies in GI market
Why You Must Buy This Report:
This 180+ paged report features 47 figures which includes graphs and charts,
28 tables, insight, and include the latest developments in the
gastrointestinal market with up-to-date analysis.
This report will give you the understanding you require to gain that
competitive edge in the GI market. This large revenue producing therapeutic
area is in the top ten of the largest earning revenues in the pharma industry.
Therefore, it is vital that the latest gastrointestinal report is brought
without fail.
The revenue forecasts generated in this report are highly accurate and are
determined by the market and its future prospects in terms of patent
protection, generic competition, life-cycle management, licensing agreements
and market activity. The forecast runs up to 2012. Therefore it gives your
company sound understanding of how GI drug will behave up until that time.
Key questions that this report answers:
- What are the most influential GI disorders and their impacts?
- Which drugs are dominating their classes in the GI market?
- What is the revenue potential in 2012 for these drugs?
- What market activity is occurring? (What are pharma companies doing?) What
is the potential population treatment in the major global markets up to 2012?
- Which is the status of the GI pipeline?
Unique benefits to you when you order this report:
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using hard
drive space
- Primary research throughout. You will not find this information anywhere
else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
View Cart
